AMRN: the cash flow

MyFinsight

For the quarter ending 2025-09-30, AMRN had -$25,074K decrease in cash & cash equivalents over the period.

Cash Flow	2025-09-30	2025-06-30
Product	136,210	-
Licensing And Royalty	28,217	-
Total revenue, net	164,427	-
Less cost of goods sold	66,728	-
Gross margin	97,699	-
Selling	18,582	-
General and administrative	32,185	-
Research and development	5,216	-
Payroll and payroll related expense	43,250	-
Non-cash stock -based compensation expense	10,146	-
Restructuring	32,165	-
Total operating expenses	141,544	-
Operating loss	-43,845	-
Interest income, net	8,277	-
Other income, net	372	-
Loss from operations before taxes	-35,196	-
Benefit from (provision for) income taxes	2,378	-
Net loss	-7,738	-29,836
Depreciation and amortization	1	2
Accretion of investments	830	2,189
Stock-based compensation	1,956	10,366
Amortization of intangible asset	866	1,457
Accounts receivable, net	8,179	-3,149
Inventory	-17,021	-19,958
Prepaid and other current assets	12,021	5,239
Other long-term assets	-26	-78
Interest receivable	-29	-420
Accounts payable and other current liabilities	-3,713	5,997
Other long-term liabilities	-115	-16
Net cash used in operating activities	-12,697	4,147
Maturities of securities	57,000	105,300
Purchases of securities	69,129	80,826
Net cash provided by (used in) investing activities	-12,129	24,474
Proceeds from issuance of common stock under employee stock purchase plan	0	57
Taxes paid related to stock-based awards	248	1,839
Net cash used in financing activities	-248	-1,782
Net increase (decrease) in cash and cash equivalents and restricted cash	-25,074	26,839
Cash and cash equivalents at beginning of period	121,338	-
Cash and cash equivalents at end of period	123,103	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.